TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03446846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as two Placebo capsules as a single dose once daily
Study: NCT04139798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution (0.6% sodium chloride solution)
Study: NCT00120302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching vehicle cream
Study: NCT01841463
Drug: P1446A-05
Approvals — FDA: no, EMA: no, PMDA: no
Description: - In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) \& vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. The next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The max tolerated dose (MTD) of P1446A-05 \& vemurafenib co-administered will be determined. In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, \& 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity to determine efficacy of the co-administration. Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples \& undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration.
Study: NCT01281514
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00005804
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00088088
Drug: STA 4783
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01004991
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 on Day 8 of each of 6 cycles
Study: NCT01004991
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 on Day 8 of each of 6 cycles
Study: NCT03524508
Drug: 5-FU/LV
Approvals — FDA: no, EMA: no, PMDA: no
Description: The recommended dose and regimen of dl-LV 400mg/m2 or l-LV 200mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks
Study: NCT00567814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily
Study: NCT00389259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo q4h
Study: NCT00165191
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01393574
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 mg for body weight \<40kg, 6 mg for body weight \>40kg, once a day 30-60 minutes before sleep
Study: NCT04177862
Drug: Sublingual Sufentanil
Normalized name: sufentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mcg of sublingual sufentanil
Study: NCT04177862
Drug: IV Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mcg of IV fentanyl
Study: NCT00544297
Drug: PEP005 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two day application, 0.05%
Study: NCT03121053
Drug: hypotone saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002496
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002496
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02894684
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 days of IV Colistin plus one of Tazocin/Ceftazidime/Meropenem/Aztreonam/Fosfomycin
Study: NCT00048074
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg iv every 2 months
Study: NCT00048074
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg po daily
Study: NCT00048074
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg iv every 3 months
Study: NCT03443973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to gantenerumab will be administered as per the schedule specified in the respective arm.
Study: NCT01887535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as an oral suspension formulation.
Study: NCT03450122
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02778789
Drug: TNF-alpha Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with TNF-Inhibitors either i.v. or s.c. according to the label
Study: NCT02773641
Drug: Sterile Saline Solution
Normalized name: Blairex Sterile Saline Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02851472
Drug: Inhaled Nitric Oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitric oxide gas will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems adapted specifically for this study.
Study: NCT02851472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gas (nitrogen) will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems specifically adapted for this study.
Study: NCT01521403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x1 tablet per day for 10 days
Study: NCT03333278
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamine 200mg every 12 hours i.v. while in ICU, until shock resolution for a maximum of ten days
Study: NCT03333278
Drug: Hydrocortisone,
Normalized name: Hydrocortisone, Rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 50mg every 6 hours i.v while in ICU, until shock resolution or for a maximum of 7 days, then tapered or stopped.
Study: NCT00713518
Drug: 3 mg PF-04523655
Normalized name: fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00713518
Drug: 1 mg PF-04523655
Normalized name: fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02287311
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion.
Study: NCT00501917
Drug: G-CSF with/without darbepoetin, peripheral blood stem cell infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02170077
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 2-093 (tablets) administered at increasing daily doses of 400 mg, 800 mg and 1200 mg once-daily or twice-daily, oral route
Study: NCT02170077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets administered orally
Study: NCT03141827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, nasal spray, single dose
Study: NCT00533676
Drug: MK0524A, /Duration of Treatment : 8 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00533676
Drug: Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00131261
Drug: PXD101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03241901
Drug: Artemether-Lumefantrine Tab 20-120mg
Normalized name: Artemether/lumefantrine
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-Lumefantrine Tablet 20-120mg
Study: NCT01939418
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afinitor 5mg qd. po.
Study: NCT00296621
Drug: L-Glutamine
Normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Glutamine
Study: NCT00296621
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00787644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (inert tablet)
Study: NCT01930006
Drug: MGCD265
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01369888
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/m\^2, intravenous (IV) (in the vein) x 2 days
Study: NCT04606602
Drug: SLN360
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLN360 for subcutaneous (s.c.) injection
Study: NCT04606602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride for subcutaneous (s.c.) injection
Study: NCT00361348
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01798056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.
Study: NCT04328844
Drug: IOA-244
Approvals — FDA: no, EMA: no, PMDA: no
Description: IOA-244 will be administered orally once daily (QD)
Study: NCT04172441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for dasiglucagon
Study: NCT00670748
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
Study: NCT03172988
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 2 ml is administered before anesthesia induction.
Study: NCT04489173
Drug: trifluridine/tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study medication should be started within 3 days after completion of screening and continue until a study treatment discontinuation criterion is met.~Trifluridine/tipiracil will be administered orally BID on days 1 through 5, with the first dose administered in the morning of day 1 of each cycle and the last dose administered in the evening of day 5, followed by a recovery period from day 6 through day 7. Trifluridine/tipiracil will be administered orally BID on days 8 through 12, with the first dose administered in the morning of day 8 of each cycle and the last dose administered in the evening of day 12, followed by a recovery period from day 13 through day 28. Each cycle will be 28 days.
Study: NCT04773366
Drug: Prednisone+Cytarabine+vincristine+Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 1 Consolidation continuation treatment (W7\~W22) . Prednisone 40mg/m2 d1-5 q3w (w7,10,13,16,19,22); VCR 1.5/m2 iv d1 q3w (w7,10,13,16,19,22); Cytarabine 100mg/m2 iv/IH d1-4 q3w (w7,10,13,16,19,22); 6-MP 50mg/m2/d,po,qn
Study: NCT02864290
Drug: ASP1235
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous (IV) infusion
Study: NCT04773366
Drug: Prednisone+Cytarabine+vincristine+Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 1 Maintenance continuation treatment (W25\~52) . Prednisone 40mg/m2 d1-5 q3w; Vincristine 1.5/m2 iv d1 q3w; Cytarabine 100mg/m2 iv/IH d1-4 q6w ×3 times (w25,31,37); 6-MP 50mg/m2/d,po,qn
Study: NCT04773366
Drug: Prednisone+vincristine+Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 2 continuation treatment (W7\~W52) . Prednisone 40mg/m2 d1-5 q3w; VCR 1.5/m2 iv d1 q3w; 6-MP 50mg/m2/d,po,qn
Study: NCT04070157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
Study: NCT03638648
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 2500mg/m2/day, d1-d14, every 3 weeks a cycle for 8 cycles
Study: NCT02096406
Drug: ACE/ARB continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE/ARB will be taken the morning of surgery with a sip of water
Study: NCT02096406
Drug: ACE/ARB withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE/ARB will be stopped 48 hours prior to surgery
Study: NCT00735436
Drug: Gliadel/Avastin/CPT-11
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01342211
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
Study: NCT01745458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT03010046
Drug: ANX005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose intravenous infusion
Study: NCT03010046
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline intravenous infusion
Study: NCT00684008
Drug: CYT107 - Recombinant glycosylated human interleukin 7.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with CYT107 60 to 210 days post transplantation, in 3 successive cohorts of 3 patients. Escalating doses of CYT107 will be given to successive cohorts. Patients will receive 1 dose of CYT107 by the subcutaneous route, once a week for 3 weeks. Dose level 1: 10 mcg/kg/dose for 3 doses; Dose level II: 20 mcg/kg/dose for 3 doses; Dose level III: 30 mcg/kg/dose for 3 doses. Only 1 treatment course for this initial study.
Study: NCT00565084
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 800 mg ibuprofen in one of the three treatment periods.
Study: NCT00565084
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo to ibuprofen in two of the three treatment periods.
Study: NCT00275912
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00727246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with placebo for 6 weeks
Study: NCT04594213
Drug: NT 201
Normalized name: Fluarix Quadrivalent 2013-2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
Study: NCT04594213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
Study: NCT05812872
Drug: Toothgraft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Particulate dentin
Study: NCT05812872
Drug: Allograft
Normalized name: Ascent Human Amniotic Allograft 15mg Tissue Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineralized corticocancellous allograft
Study: NCT05812872
Drug: Alloplast
Normalized name: PASTE,COLOPLAST #2650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta tri-calcuim phosphate
Study: NCT03586427
Drug: AGN-241751
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-241751 administered orally as a single tablet
Study: NCT03586427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally as a single tablet
Study: NCT02906527
Drug: Non-exposed group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-exposed group / Patients receiving VKA
Study: NCT02906527
Drug: Exposed group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposed group / Patients receiving DOAC
Study: NCT01857817
Drug: VT-122
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules.
Study: NCT01193478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, oral, once daily for 3 days
Study: NCT01857817
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo capsules will be prepared to match the active drug.
Study: NCT02392624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to omalizumab administered SC Q4W.
Study: NCT03036202
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is truly an observational study to determine T1/2 for epinephrine and time to peak concentration following a single dose of epinephrine in a cardiac arrest setting
Study: NCT00193661
Drug: Testosterone Gel (1%)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03763877
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT02528981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04359316
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Azithromycin in COVID-19 patients.
Study: NCT02538224
Drug: 2.5%ketoprofen gel + 3 % doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: GroupA:(0.05cc, mixed gel) be put into the periodontal pocket using an insulin syringe.~Intervention category Treatment: drugs
Study: NCT02538224
Drug: :2.5%ketoprofen gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: GroupB:2.5%ketoprofen gel which be inserted into the periodontal pocket using an insulin syringe .
Study: NCT00072319
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01106690
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One matching placebo capsule orally (by mouth) once daily for 26 weeks with stable doses of metformin and pioglitazone.
Study: NCT02346721
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg tablet administered orally once daily
Study: NCT03646552
Drug: THX-110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive THX-110 in the following regimen:~Dronabinol will be slowly titrated in the first 10 days of the study and PEA will be given in a constant dose of 800mg per day for the entire duration of the study.~Patients will be followed for a total of 30 days.
Study: NCT02641782
Drug: IL-2 i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mio U/m²xd d1-4 continuous infusion i.v. and 4.5 mio U/m²xd d8-11 continuous infusion i.v. in cycles 2,4
Study: NCT02641782
Drug: IL-2 s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mio U/m² i.v. test dosis for 30min. i.v. at least 2h before first subcutaneous (s.c.) application. 6 mio U/m²xd d1-5 and 8-12 s.c. in cycles 2,4
Study: NCT03408392
Drug: Test formulation A
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation: SKF101804 will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a fruit flavor and odor.
Study: NCT03408392
Drug: Reference formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a strawberry flavor and odor.
Study: NCT02097264
Drug: NNC0109-0012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection administered subcutaneously (s.c. - under the skin). 240 mg NNC0109-0012 will be administered weekly for 12 weeks
Study: NCT02097264
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection administered subcutaneously (s.c. - under the skin).~1 active adalimumab injection and 2 placebo injections per active treatment (every other week), and 3 placebo injections on placebo visits (alternative weeks).
Study: NCT01749215
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT01526577
Drug: LC23-1306
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC23-1306 10, 30, 100, 200, 400, 600 mg Placebo 10, 30, 100, 200, 400, 600 mg
Study: NCT01526577
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC23-1306 placebo
Study: NCT03677557
Drug: 16,5% Cutaquig
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with primary or secondary immunodefiiciney disease and who do not tolerate other immunoglobulin treatments will be asked to use 16.5% Cutaquig
Study: NCT00346697
Drug: Omega-3 fatty acid administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOVAZA 1 gram capsules, 4 capsules daily
Study: NCT00346697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn-oil placebo
Study: NCT00326859
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04287790
Drug: Acamprosate, naltrexone, or disulfiram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased receipt of medications for alcohol use disorder facilitated by the implementation intervention.
Study: NCT03599089
Drug: CA-008
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-dose wound infiltration prior to surgical incision closure
Study: NCT03599089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-dose wound infiltration prior to surgical incision closure
Study: NCT03599089
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg IV administered intraoperatively